Main Article Content

Mega Novitasari
Hidayah Karuniawati

Page: 2033-2043

Abstract

Introduction: Multidrug-Resistant Tuberculosis (MDR-TB) is a disease caused by resistant Mycobacterium tuberculosis and is a leading cause of death worldwide. Several factors influence treatment outcomes in MDR-TB patients. Objective: This study aims to analyze factors that play an important role in the treatment outcome of MDR-TB patients. Methods: The method used in this study was a systematic literature review with quantitative data. The literature used in this study was obtained through online searches using reputable databases, namely Science Direct, PubMed, and Google Scholar with covering articles from 2020 to 2025. Results: A total of 8 articles met the inclusion criteria and were analyzed in this systematic review. Treatment success rates for MDR-TB patients in several countries ranged from 54,1% to 84.74%. Factors associated with treatment outcome included gender, age, education level, distance to treatment center, body mass index (BMI), time to diagnosis more than 30 days, delayed culture conversion time more than 2 months, history of previous TB treatment, comorbidities, extent of lung lesions and bronchiectasis, and drug side effects. Conclusion: The success rate of MDR-TB treatment in across countries still varies. The success of MDR/RR-TB treatment is influenced by a combination of demographic, clinical, social, and healthcare access factors. Factors such as younger age, good nutritional status, higher education level, and adequate access to healthcare services have been shown to increase the likelihood of treatment success. Conversely, treatment failure (outcome failure) is influenced by the presence of comorbidities, older age, previous treatment history, drug resistance, adverse effects of therapy, delayed diagnosis, and low patient adherence. Early identification of risk factors is essential for optimal management and increased success of MDR-TB treatment.

Downloads

Download data is not yet available.

Article Details

How to Cite
Novitasari, M., & Karuniawati , H. (2026). Systematic Literature Review: Factors Influencing Treatment Outcomes in Multidrug-Resistant Tuberculosis Patients. Journal of Pharmaceutical and Sciences, 9(2), 2033–2043. https://doi.org/10.36490/journal-jps.com.v9i2.1502
Section
Review Article

References

WHO. Global tuberculosis report 2018. World Health Organization; 2018.

Barberis I, Bragazzi NL, Galluzzo L, Martini M. The history of tuberculosis: from the first historical records to the isolation of Koch’s bacillus. vol. 58. 2017.

Kesehatan K. Petunjuk Teknis Penatalaksanaan Tuberkulosis Resistan Obat di Indonesia. 2024.

WHO. 2024 Global tuberculosis report. 2024.

Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, Wejse C, et al. MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. International Journal of Infectious Diseases 2020;92:S15–25. https://doi.org/10.1016/j.ijid.2020.01.042. DOI: https://doi.org/10.1016/j.ijid.2020.01.042

Pradipta IS, Idrus LR, Probandari A, Lestari BW, Diantini A, Alffenaar JWC, et al. Barriers and strategies to successful tuberculosis treatment in a high-burden tuberculosis setting: a qualitative study from the patient’s perspective. BMC Public Health 2021;21. https://doi.org/10.1186/s12889-021-12005-y. DOI: https://doi.org/10.1186/s12889-021-12005-y

Wakjira MK, Sandy PT, Mavhandu-Mudzusi AH. Treatment outcomes of patients with MDR-TB and its determinants at referral hospitals in Ethiopia. PLoS One 2022;17. https://doi.org/10.1371/journal.pone.0262318. DOI: https://doi.org/10.1371/journal.pone.0262318

Eshiet UI, Akpan MR, Jackson IL, Uduak AS, Udiminue DS. Treatment outcomes in patients with multi-drug resistant tuberculosis. Medicine India 2024;3:77–82. https://doi.org/10.25259/medindia_18_2024. DOI: https://doi.org/10.25259/MEDINDIA_18_2024

Babalik A, Balikçi A, Turkar A, Teke NH, Demir FK, Yavuz S, et al. Affecting Factors Unfavorable Treatment Outcomes of Rifampicin-resistant/Multidrug-resistant Tuberculosis Patients Treated with Long-term Regimen. Int J Mycobacteriol 2024;13:265–74. https://doi.org/10.4103/ijmy.ijmy_132_24. DOI: https://doi.org/10.4103/ijmy.ijmy_132_24

Chen B, Chen X, Ren Y, Peng Y, Wang F, Zhou L, et al. Treatment cascade for patients with multidrug- or rifampicin-resistant tuberculosis and associated factors with patient attrition in southeastern China: a retrospective cohort study. J Infect Public Health 2023;16:1073–80. https://doi.org/10.1016/j.jiph.2023.05.012. DOI: https://doi.org/10.1016/j.jiph.2023.05.012

Ma JB, Zeng LC, Ren F, Dang LY, Luo H, Wu YQ, et al. Development and validation of a prediction model for unsuccessful treatment outcomes in patients with multi-drug resistance tuberculosis. BMC Infect Dis 2023;23. https://doi.org/10.1186/s12879-023-08193-0. DOI: https://doi.org/10.1186/s12879-023-08193-0

Soeroto AY, Nurhayati RD, Purwiga A, Lestari BW, Pratiwi C, Santoso P, et al. Factors associated with treatment outcome of MDR/RR-TB patients treated with shorter injectable based regimen in West Java Indonesia. PLoS One 2022;17. https://doi.org/10.1371/journal.pone.0263304. DOI: https://doi.org/10.1371/journal.pone.0263304

Panford V, Kumah E, Kokuro C, Adoma PO, Baidoo MA, Fusheini A, et al. Treatment outcomes and associated factors among patients with multidrug-resistant tuberculosis in Ashanti Region, Ghana: a retrospective, cross-sectional study. BMJ Open 2022;12. https://doi.org/10.1136/bmjopen-2022-062857. DOI: https://doi.org/10.1136/bmjopen-2022-062857

Iqbal F, Defer MK, Latif A, Hadi H. Understanding how geographic, demographic and treatment history impact health outcomes of patients with multi-drug-resistant tuberculosis in Pakistan, 2014-2017. Epidemiol Infect 2020;148. https://doi.org/10.1017/S0950268820002307. DOI: https://doi.org/10.1017/S0950268820002307

Akhir Pengobatan Pasien Tuberkulosis Multidrug Resistan di Jawa Timur Tahun H, Fitriya L, Dwi Artanti K, Author C. Treatment Outcomes Of Multidrug Resistant Tuberculosis Patients in East Java from 2014 to 2017 2020;8:141–8. https://doi.org/10.20473/jbe.v8i22020. DOI: https://doi.org/10.20473/jbe.V8I22020.141-148

Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JWC, Anderson LF, Baghaei P, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. The Lancet 2018;392:821–34. https://doi.org/10.1016/S0140-6736(18)31644-1. DOI: https://doi.org/10.1016/S0140-6736(18)31644-1

Bastos ML, Cosme LB, Fregona G, do Prado TN, Bertolde AI, Zandonade E, et al. Treatment outcomes of MDR-tuberculosis patients in Brazil: A retrospective cohort analysis. BMC Infect Dis 2017;17. https://doi.org/10.1186/s12879-017-2810-1. DOI: https://doi.org/10.1186/s12879-017-2810-1

Lin C Bin, Sun HC, Chiang CY, Wu CW, Chou HW, Tang TQ, et al. Treatment outcomes for multidrug-resistant tuberculosis in Eastern Taiwan. Tzu Chi Med J 2019;31:35–9. https://doi.org/10.4103/tcmj.tcmj_18_18. DOI: https://doi.org/10.4103/tcmj.tcmj_18_18

Asih Ruhmiati AR, Hernandia Distinarista, Tutik Rahayu. Hubungan Tingkat Pengetahuan dengan Kepatuhan Minum Obat Antihipertensi di Ruang Kasablanka RSU Islam Harapan Anda Tegal. Diagnosa: Jurnal Ilmu Kesehatan Dan Keperawatan 2025;3:95–105. https://doi.org/10.59581/diagnosa-widyakarya.v3i4.5544. DOI: https://doi.org/10.59581/diagnosa-widyakarya.v3i4.5544

Robsky KO, Robsky KO, Hughes S, Kityamuwesi A, Kendall EA, Kitonsa PJ, et al. Is distance associated with tuberculosis treatment outcomes? A retrospective cohort study in Kampala, Uganda. BMC Infect Dis 2020;20. https://doi.org/10.1186/s12879-020-05099-z. DOI: https://doi.org/10.1186/s12879-020-05099-z

Faralina M, Yunis T, Wahyono M, Wijaya F. Tinjauan Literatur: Keterlambatan Memulai Pengobatan Sebagai Salah Satu Faktor Risiko Hasil Akhir Pengobatan Tuberkulosis Yang Buruk. n.d.

Wulandari E dan RS. Determinan Kegagalan Pengobatan pada Pasien Tuberkulosis Sensitif Obat Dewasa di Provinsi Jawa Tengah Tahun 2022. Jurnal Epidemiologi Kesehatan Indonesia 2024;8. https://doi.org/10.7454/epidkes.v8i1.1100. DOI: https://doi.org/10.7454/epidkes.v8i1.1100

Chakaya J, Khan M, Ntoumi F, Aklillu E, Fatima R, Mwaba P, et al. Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts. International Journal of Infectious Diseases 2021;113:S7–12. https://doi.org/10.1016/j.ijid.2021.02.107. DOI: https://doi.org/10.1016/j.ijid.2021.02.107

Kwak N, Kim JY, Kim HJ, Kwon BS, Lee JH, Mok J, et al. High-Dose Rifampicin for 3 Months after Culture Conversion for Drug-Susceptible Pulmonary Tuberculosis. Tuberc Respir Dis (Seoul) 2025;88:170–80. https://doi.org/10.4046/trd.2024.0099. DOI: https://doi.org/10.4046/trd.2024.0099